Anafranil SR, 75 mg 10 pcs

Anafranil SR is a tricyclic antidepressant, an inhibitor of noradrenaline and serotonin reuptake. The therapeutic effect of Anafranil SR is thought to be due to its ability to inhibit the neuronal reuptake of noradrenaline (NA) and serotonin (5-HT) released into the synaptic gap, the most important being inhibition of serotonin reuptake. Anafranil SR also has a broad spectrum of other pharmacological actions: alpha1-adrenolytic, anticholinergic, antihistamine and antiserotoninergic (5-HT receptor blockade).

Anafranil SR acts on the depressive syndrome in general, including especially on such its typical manifestations as psychomotor retardation, depressed mood and anxiety. Clinical effect is usually observed after 2-3 weeks of treatment. In addition, Anafranil SR has a specific (different from its antidepressant effect) effect in obsessive-compulsive disorders.

The action of Anafranil SR in chronic pain syndromes, whether or not due to somatic diseases, is probably due to the facilitation of nerve impulse transmission mediated by serotonin and noradrenaline.

Indications

Mental disorders, Pain, Phobias and panic attacks, Enuresis, Depression, Obsessive-compulsive neurosis

Adults:
– Treatment of depressive states of various etiology, proceeding with different symptomatology: endogenous, reactive, neurotic, organic, masked, involutionary forms of depression; depression in patients with schizophrenia and psychopathies; depressive syndromes occurring in old age, caused by chronic pain syndrome or chronic somatic diseases; Depressive mood disorders of reactive, neurotic or psychopathic nature;
– Obsessive-compulsive syndromes;
– Chronic pain syndrome;
– Phobias and panic attacks;
– Cataplexy, associated with narcolepsy.
Children and adolescents:
– obsessive-compulsive syndromes;
– nocturnal enuresis (only in patients over 5 years of age and if organic causes of the disease are excluded).

Active ingredient

Clomipramine

Composition

1 tablet contains clomipramine hydrochloride 75 mg

How to take, the dosage

The doses of the drug are adjusted to the patient’s individual condition. The aim of treatment is to achieve optimal effect with doses as low as possible and to increase them cautiously, especially in elderly patients and adolescents who are generally more sensitive to Anafranil SR than patients in intermediate age groups. The initial daily dose is 75 mg (25 mg 2-3 times a day).

Special Instructions

Tricyclic antidepressants are known to decrease seizure threshold, therefore Anafranil SR should be used with special caution in patients with epilepsy.

Patients who experience drowsiness or other CNS disturbances (including blurred vision) while using Anafranil SR should not drive a vehicle, operate machinery, or perform other activities requiring increased attention and quick reaction time.

Contraindications

– hypersensitivity to clomipramine and other components of the drug, cross-sensitivity to tricyclic antidepressants of dibenzazepine group;
– concurrent use of MAO inhibitors, as well as a period of less than 14 days before and after their use;
– concomitant use of selective MAO inhibitors of type A reversible action (such as moclobemide);
– recently suffered myocardial infarction;
– congenital QT interval prolongation syndrome.

The drug is not recommended for use in pregnancy and during breastfeeding.
The drug is not recommended for use in children under 5 years of age.

Side effects

Others: after abrupt withdrawal or rapid dose reduction of Anafranil SR the following symptoms frequently occur: nausea, vomiting, abdominal pain, diarrhea, insomnia, headache, irritability, anxiety.

The adverse events observed are usually mild and transient, resolving with continuation of treatment or after reducing the dose of Anafranil SR. They do not always correlate with the plasma concentration of the active substance or with the dose. Some adverse events, such as general weakness, sleep disturbances, agitation, anxiety, constipation, dry mouth, are often difficult to distinguish from manifestations of depression.

If serious side effects from the nervous system or mental status develop, Anafranil SR should be discontinued. The elderly are particularly sensitive to the effects of Anafranil SR on the nervous system, cardiovascular system, effects of the drug on mental status, and the anticholinergic effects of Anafranil SR.